| 1 |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 ancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2 |
陈旭，牛凯，孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(3): 341-348.
|
| 3 |
Hellmann MD, Paz-Ares L, Bernabe CR, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21): 2020-2031.
|
| 4 |
Duchemann B, Remon J, Naigeon M, et al. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(6): 2937-2954.
|
| 5 |
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
|
| 6 |
Journal of thoracic oncology: official publication of the international association for the study of lung cancer[J]. J Thorac Oncol, 2018, 13(7): 978-986.
|
| 7 |
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152.
|
| 8 |
Ayati N, Lee ST, Zakavi SR, et al. Response evaluation and survival prediction after PD-1 immunotherapy in patients with non-small cell lung cancer: comparison of assessment methods[J]. J Nucl Med, 2021, 62(7): 926-933.
|
| 9 |
Goo HW, Goo JM. Dual-energy CT: new horizon in medical imaging[J]. Korean J Radiol, 2017, 18(4): 555-569.
|
| 10 |
Chen Y, Jiang J, Yan C, et al. Prediction of tumor regression grade in far-advanced gastric cancer after preoperative immuno-chemotherapy using dual-energy CT-derived extracellular volume fraction[J]. Eur Radiol, 2025, 35(1): 93-104.
|
| 11 |
Wiley N, Zecevic M, Ho V, et al. Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients[J]. Eur Radiol, 2025, 35(8): 4417-4428.
|
| 12 |
Brendlin AS, Peisen F, Almansour H, et al. A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage Ⅳ melanoma[J]. J Immunother Cancer, 2021, 9(11): e003261.
|
| 13 |
Chen L, Zhao Y, Tian X, et al. Deep learning analysis based on dual-energy CT-derived iodine map for predicting PD-L1 expression in gastric cancer: a multicenter study[J]. Acad Radiol, 2026: S1076-6332(25)01168-7.
|
| 14 |
Sun C, Ma X, Meng F, et al. Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC[J]. Neoplasia, 2024, 50: 100977.
|
| 15 |
Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009, 50 Suppl 1(Suppl 1): 122S-50S.
|
| 16 |
Rossi G, Bauckneht M, Genova C, et al. Comparison between 18F-FDG PET-based and CT-based criteria in non-small cell lung cancer patients treated with nivolumab[J]. J Nucl Med, 2020, 61(7): 990-998.
|
| 17 |
Tricarico P, Chardin D, Martin N, et al. Total metabolic tumor volume on 18F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy[J]. J Immunother Cancer, 2024, 12(4): e007628.
|
| 18 |
Kaira K, Yamaguchi O, Naruse I, et al. Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer[J]. Cancer Imaging, 2023, 23(1): 23.
|
| 19 |
Cho SY, Lipson EJ, Im HJ, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma[J]. J Nucl Med, 2017, 58(9): 1421-1428.
|
| 20 |
Riberdy V, Guida A, Rioux J, et al. Radiomics in preclinical imaging research: methods, challenges and opportunities[J]. Npj Imaging, 2025, 3(1): 45.
|
| 21 |
Rallis KS, Makker S, Ghose A, et al. Assessing radiological response to immunotherapy in lung cancer: an evolving arena[J]. Cancer Diagn Progn, 2024, 4(1): 1-8.
|
| 22 |
Unterrainer M, Ruzicka M, Fabritius MP, et al. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions[J]. Eur Radiol Exp, 2020, 4(1): 63.
|
| 23 |
Mayerhoefer ME, Materka A, Langs G, et al. Introduction to radiomics[J]. J Nucl Med, 2020, 61(4): 488-495.
|
| 24 |
Wang J, Wang J, Huang X, et al. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer[J]. BMC Med imaging, 2024, 24(1): 45.
|
| 25 |
Liu Z, Yao Y, Zhao M, et al. Radiomics models derived from arterial-phase-enhanced CT reliably predict both PD-L1 expression and immunotherapy prognosis in non-small cell lung cancer: a retrospective, multicenter cohort study[J]. Acad Radiol, 2025, 32(1): 493-505.
|
| 26 |
Lin P, Wang H, Zou B, et al. A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances[J]. Transl Lung Cancer Res, 2025, 14(10): 4576-4603.
|
| 27 |
Wu Y, Zhang W, Liang X, et al. Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy[J]. J Transl Med, 2025, 23(1): 393.
|
| 28 |
Zhang Z, Liu Z, Yang M, et al. Multi-institutional development and validation of habitat imaging for predicting outcomes of first-line immunotherapy in advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2025, 14(9): 3886-3899.
|
| 29 |
Lin X, Liu Z, Zhou K, et al. Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC[J]. Br J Cancer, 2025, 132(6): 558-568.
|
| 30 |
Abbas E, Fanni SC, Bandini C, et al. Delta-radiomics in cancer immunotherapy response prediction: A systematic review[J]. Eur J Radiol Open, 2023, 11: 100511.
|
| 31 |
Khorrami M, Prasanna P, Gupta A, et al. Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer[J]. Cancer Immunol Res, 2020, 8(1): 108-119.
|
| 32 |
Wang T, Chen L, Bao X, et al. Short-term peri- and intra-tumoral CT radiomics to predict immunotherapy response in advanced non-small cell lung cancer[J]. Transl Lung Cancer Res, 2025, 14(3): 785-797.
|
| 33 |
Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis[J]. Med Image Anal, 2017, 42: 60-88.
|
| 34 |
Xu T, Liu X, Chen Y, et al. CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer[J]. BMC Med Imaging, 2024, 24(1): 196.
|
| 35 |
Mu W, Jiang L, Shi Y, et al. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images[J]. J Immunother Cancer, 2021, 9(6): e002118.
|
| 36 |
Yu J, Yang B, Wang J, et al. 2D CNN versus 3D CNN for false-positive reduction in lung cancer screening[J]. J Med Imaging (Bellingham), 2020, 7(5): 051202.
|
| 37 |
Ilesanmi AE, Ilesanmi TO, Ajayi BO. Reviewing 3D convolutional neural network approaches for medical image segmentation[J]. Heliyon, 2024, 10(6): e27398.
|
| 38 |
Saad MB, Hong L, Aminu M, et al. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study[J]. Lancet Digit Health, 2023, 5(7): e404-e420.
|
| 39 |
Wang C, Li Y, Ji Y, et al. Predictions of response in non-small cell lung cancer patients treated with immune checkpoint Inhibitors using clinical data, deep learning, and radiomics[J]. Acad Radiol, 2026, 33(1): 236-254.
|
| 40 |
Yuan L, Wang Q, Sun F, et al. Deep learning and inflammatory markers predict early response to immunotherapy in unresectable NSCLC: A multicenter study[J]. Biomol Biomed, 2025, 25(10): 2252-2268.
|
| 41 |
Wang Q, Deng L, Jiang D, et al. Decoding dendritic cell subtypes via integrated radiogenomics: a stacked ensemble model for predicting immunotherapy response in NSCLC[J]. FASEB , 2025, 39(21): e71133.
|
| 42 |
Wang ZJ, Liu X, Han KT, et al. Multimodal deep learning for immunotherapy response prediction and biomarker discovery in non-small cell lung cancer[J]. J Am Med Inform Assoc, 2025, 32(11): 1641-1653.
|